Eli Lilly and Company (LLY)vsRidgetech, Inc. (RDGT)
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
RDGT
Ridgetech, Inc.
$0.83
-1.59%
HEALTHCARE · Cap: $3.39M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 60178% more annual revenue ($79.67B vs $132.16M). LLY leads profitability with a 33.5% profit margin vs -0.9%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
RDGT
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+82.8%
Fair Value
$10.36
Current Price
$0.83
$9.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Every $100 of equity generates 30 in profit
Conservative balance sheet, low leverage
Revenue surging 21.4% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : RDGT
The strongest argument for RDGT centers on Price/Book, Return on Equity, Debt/Equity. Revenue growth of 21.4% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : RDGT
The primary concerns for RDGT are EPS Growth, Market Cap, Free Cash Flow.
Key Dynamics to Monitor
LLY carries more volatility with a beta of 0.50 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 39/100), backed by strong 33.5% margins and 47.7% revenue growth. RDGT offers better value entry with a 82.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Ridgetech, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
China Jo-Jo Drugstores, Inc. is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company is headquartered in Hangzhou, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?